Home   >  
Angiogenesis/Protein Tyrosine Kinase

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials


Chemical Structure Cat. No. Product Name CAS No.
Ibrutinib Racemate Chemical Structure
BCP24087 Ibrutinib Racemate 936563-87-0
Ibrutinib Racemate is the racemate of Ibrutinib.
Sunvozertinib Chemical Structure
BCP46584 Sunvozertinib 2370013-12-8
Sunvozertinib, also known as DZD9008, is an oral, potent, irreversible, and selective EGFR tyrosine kinase inhibitor. Sunvozertinib shows activity against EGFRexon20ins and other mutations. In both cell lines and xenograft models, sunvozertinib shows potent antitumor activity. In the two ongoing phase I clinical studies, sunvozertinib was tolerated up to 400 mg once daily.
RN983 Chemical Structure
BCP44110 RN983 1423129-83-2
RN983 is a selective BTK enzyme inhibitor.
BIIB068 Chemical Structure
BCP44097 BIIB068 1798787-27-5
BIIB068 is a potent, selective, reversible and orally active BTK inhibitor.
TL-895 Chemical Structure
BCP44090 TL-895 1415823-49-2
TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively.
Tolebrutinib Chemical Structure
BCP33289 Tolebrutinib 1971920-73-6
Tolebrutinib, also known as SAR442168, is a Bruton tyrosine kinase inhibitor.
Rilzabrutinib Chemical Structure
BCP43077 Rilzabrutinib 1575596-29-0
Rilzabrutinib, also known as PRN1008, is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK).
Pirtobrutinib Chemical Structure
BCP42730 Pirtobrutinib 2101700-15-4
Pirtobrutinib is a Bruton's tyrosine kinase (BTK) inhibitor and antineoplastic agent.
CNX-500 Chemical Structure
BCP40963 CNX-500 1202758-21-1
CNX-500 is a probe consisting of a covalent Btk inhibitor chemically linked to biotin.
Olmutinib dihydrochloride Chemical Structure
BCP38296 Olmutinib dihydrochloride 1842366-97-5
Olmutinib is an orally available, mutant-selective third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed for treatment of advanced and metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC).
123下一页末页共 43 条记录 1 / 5 页